Search Results - "Kourie, Hampig R."

Side-effects of checkpoint inhibitor-based combination therapy by Kourie, Hampig R, Klastersky, Jean A

“…After the dramatic and often long-standing response rates of checkpoint inhibitors as single agents, the new era for checkpoint inhibitors is combined therapy…”
Get full text

Targeting HER2 in the management of potentially resectable gastric adenocarcinoma: what are oncologists waiting for? by Gharib, Khalil El, R Kourie, Hampig

“…Marx et al. brought an answer to the latter uncertainty in HER2-positive gastric cancer when they demonstrated a high level of amplification and homogeneity of…”
Get full text

Awareness about the human papillomavirus (HPV) and HPV vaccine among medical students in Lebanon by Haddad, Sara F., Kerbage, Anthony, Eid, Roland, Kourie, Hampig R.

“…As a developing country, Lebanon lacks adequate awareness about Human papillomavirus (HPV) among its population, whether working in the medical field or not…”
Get full text

EARLY INCREASE of CA 19-9 in ADVANCED PANCREATIC CANCER RECEIVING FOLFIRINOX. Is it a sign of efficacy? by Tabchi, Samer, Kourie, Hampig R, Farhat, Fadi, Kattan, Joseph

“…Advanced pancreatic cancer (APC), one of the most aggressive tunors, was considered to be resistant to chemotherapy for decades. FOLFIRINOX (5-FU, leucovorin,…”
Get full text

Concurrent driver mutations/rearrangements in non-small-cell lung cancer by Tabchi, Samer, Kourie, Hampig R, Klastersky, Jean

“…PURPOSE OF REVIEWThe concept of mutually exclusive oncogenic driver alterations has prevailed over the past decade, but recent reports have stressed the…”
Get full text

Update on immunotherapy in the management of gallbladder cancer by Kassab, Joseph, Saba, Ludovic, Gebrael, Georges, Kais, Sami, Kassab, Rebecca, Kourie, Hampig R

“…Gallbladder cancer (GBC) is a relatively infrequent but highly lethal cancer with a poor prognosis. Management remains challenging and controversial, and most…”
Get full text

The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice by Zouein, Joseph, Haddad, Fady G, Eid, Roland, Kourie, Hampig R

“…Lung cancer is the second most common cancer worldwide and the leading cause of death among cancers. The progressive approvals of immunotherapy as first-line…”
Get full text

Tsunami of immunotherapies in the management of esophageal cancer by Kassab, Joseph, Saba, Ludovic, Kassab, Rebecca, Kourie, Hampig R

“…Esophageal cancer (EC) is relatively frequent and highly lethal cancer, being the sixth most common cause of cancer death worldwide. The progressive approvals…”
Get full text

HER2 in metastatic colorectal cancer: a new to target to remember by Bitar, Lynn, Zouein, Joseph, Haddad, Fady Gh, Eid, Roland, Kourie, Hampig R

“…Metastatic colorectal cancer is the second most common cause of cancer death. Standard chemotherapy in combination with targeted therapies represent the…”
Get full text

Predictive biomarkers in bladder cancer by Alkassis, Marwan, Kourie, Hampig R, Sarkis, Julien, Nemr, Elie

Get full text

Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review by Salloum, Antoine, Habre, Maya, Chebl, Joanna Abi, Chebl, Karen Abi, Atallah, Carl, Medawar, Georgio, Kourie, Hampig R

“…This paper presents the reported dermatological adverse events (AEs) associated with approved combinations of immunotherapy with drugs of the same class, or in…”
Get full text

NTRK genes and cancer: when arresting the fusion underlies the treatment by Gharib, Khalil El, Kourie, Hampig R

Get full text

Novel biomarkers in testicular germ cell tumors: updates of 2020 by Sarkis, Julien, R Kourie, Hampig, Alkassis, Marwan, Samaha, Ramy, Sarkis, Pierre

Get full text

BRCAness in biliary tract cancer: a new prognostic and predictive biomarker? by Hachem, Samir, Kassis, Yara, Hachem, Maria Cr, Zouein, Joseph, Gharios, Joseph, Kourie, Hampig R

“…Cholangiocarcinoma (CCA) is a rare malignancy with a very poor prognosis. Considering that most cases of CCA are diagnosed at a locally advanced stage and the…”
Get full text

Rare side-effects of checkpoint inhibitors by Kourie, Hampig R, Awada, Gil, Awada, Ahmad H

“…PURPOSE OF REVIEWThe aim of this review is to draw the attention of the physicians and oncologists on the rare side-effects of checkpoint inhibitors not…”
Get full text

Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know by Habre, Maya, Habre, Samer Bassilios, Kourie, Hampig R

“…Immune checkpoint inhibitors (ICI) represent a new revolutionary weapon in the armamentarium of anti-cancer therapies. The side effects of these new agents…”
Get full text

Uncovering the epidemiology of bladder cancer in the Arab world: A review of risk factors, molecular mechanisms, and clinical features by Abbas, Noura F., Aoude, Marc R., Kourie, Hampig R., Al-Shamsi, Humaid O.

Get full text

Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole by Assi, Tarek, Kourie, Hampig R, El Rassy, Elie, Moussa, Tania, Kattan, Joseph

“…Granulosa cell tumors of the ovaries (GCTO), the most common sex cord tumors of the female genitalia, are characterized by a remarkably favorable prognosis but…”
Get full text

The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer by Kourie, Hampig R, Ibnshamsah, Fahad, Zouein, Joseph, Naim, Nabih, Abbasi, Salah, Allahloubi, Nasr, Al-Naqqash, Manwar, Alolayan, Ashwaq, Alshehri, Ahmed, Bitar, Nizar, Bounedjar, Adda, Farsi, Abdulaziz Al, Shamsi, Humaid El, Ghali, Ramy, Jaafar, Hassan, Larbaoui, Blaha, Mahrous, Mervat, Mrabti, Hind, Nweir, Abdul Razzak, Oukkal, Mohamed, Rasul, Kakil, Razavi, Mohsen, Turfa, Rim, Khatib, Sami, Shamseddine, Ali

“…Colorectal cancer (CRC) is ranked as the third most prevalent and the second deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, the…”
Get full text

Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives by Haddad, Fady G, Kourie, Hampig R, Kattan, Joseph

“…[...]the results of BLOOM Phase I trial presented at the ASCO 2016 annual meeting supported these data by showing that osimertinib reduced CNS lesions…”
Get full text